Full-Time
Develops RNAi therapeutics using trigger molecules
$136k - $154k/yr
Cambridge, MA, USA
In Person
City Therapeutics develops RNA interference (RNAi) medicines. It works on creating next-generation trigger molecules and delivery ligands to silence disease-causing genes in the body. The core product approach uses RNAi to turn off specific genes in cells, reducing the production of harmful proteins. Delivery and targeting are tailored, so the RNAi triggers reach the right tissues more effectively than before. Compared with peers, City Therapeutics emphasizes proprietary trigger chemistry and ligand-based delivery to improve precision and expand the range of diseases that can be treated, aiming for strong therapeutic impact rather than relying on traditional small molecules or antibodies. The company’s goal is to advance and apply RNAi-based medicines across multiple conditions by leveraging human genetics insights, partnerships, and focused development to bring effective gene-silencing therapies to patients.
Company Size
51-200
Company Stage
Series A
Total Funding
$135M
Headquarters
Massachusetts
Founded
N/A
Help us improve and share your feedback! Did you find this helpful?
People at City Therapeutics who can refer or advise you
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Holidays
Flexible Work Hours
Remote Work Options
Hybrid Work Options
Life Insurance
Disability Insurance
Wellness Program
Mental Health Support
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Conference Attendance Budget
Professional Development Budget
Family Planning Benefits
Fertility Treatment Support
Stock Options
Company Equity
City Therapeutics launches with $135M to lead the future of RNAi-based medicine; led by founding Alnylam CEO and RNAi pioneer Dr. John Maraganore